Compound class:
Synthetic organic
Comment: This compound is an orally bioavailable and selective inhibitor of the class III phosphoinositide 3-kinase VPS34 [4], that was developed for potential to modulate autophagy, as an anti-tumour mechanism. Development was discontinued due to potential unfavourable on-target toxicity (e.g. GI tract necropsy in rats [3]) arising from sustained inhibition of VPS34 kinase activity. Inhibition of VPS34 or deletion of its gene (PIK3C3) is reported to not only affect autophagy, but also alter cellular energy metabolism and disrupt membrane trafficking, phagocytosis and cytokinesis [1,5]. The mechanism of compound 5's interaction with VPS34 can be used to direct the search for inhibitors for other kinases which avoid VPS34 as an off-target [2].
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
References |
1. Bilanges B, Alliouachene S, Pearce W, Morelli D, Szabadkai G, Chung YL, Chicanne G, Valet C, Hill JM, Voshol PJ et al.. (2017)
Vps34 PI 3-kinase inactivation enhances insulin sensitivity through reprogramming of mitochondrial metabolism. Nat Commun, 8 (1): 1804. [PMID:29180704] |
2. Garcia-Barrantes PM. (2022)
Selective VPS34 Inhibitors: High Efficiency Design by Profiting from Small Structural Differences. J Med Chem, 65 (17): 11497-11499. [PMID:35998347] |
3. Henley ZA, Amour A, Barton N, Bantscheff M, Bergamini G, Bertrand SM, Convery M, Down K, Dümpelfeld B, Edwards CD et al.. (2020)
Optimization of Orally Bioavailable PI3Kδ Inhibitors and Identification of Vps34 as a Key Selectivity Target. J Med Chem, 63 (2): 638-655. DOI: 10.1021/acs.jmedchem.9b01585 [PMID:31855425] |
4. Hu DX, Patel S, Chen H, Wang S, Staben ST, Dimitrova YN, Wallweber HA, Lee JY, Chan GKY, Sneeringer CJ et al.. (2022)
Structure-Based Design of Potent, Selective, and Orally Bioavailable VPS34 Kinase Inhibitors. J Med Chem, 65 (17): 11500-11512. [PMID:34779204] |
5. Kuma A, Komatsu M, Mizushima N. (2017)
Autophagy-monitoring and autophagy-deficient mice. Autophagy, 13 (10): 1619-1628. [PMID:28820286] |